SecBot SecBot
SECBOTREPLAY Home › Report › CELC

CELC · Celcuity announced FDA approval of REVTORPYK (gedatolisib) for…

Celcuity Inc. · PRESS-RELEASE filed Jul 14, 2026 at 16:53 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Jul 14, 2026 at 16:53 ET

Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation, based on Phase 3 VIKTORIA-1 data showing a 76% reduction in risk of progression or death. This is the company's first approved product, transforming it from a clinical-stage biotech to a commercial-stage company, with launch expected in late Q3 2026.

  • FDA approved REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutation
  • First and only FDA-approved therapy inhibiting all class I PI3K isoforms and mTORC1/2
  • Phase 3 VIKTORIA-1: REVTORPYK triplet reduced risk of progression or death by 76% (HR=0.24) vs fulvestrant
  • Median PFS: 9.3 months (triplet) vs 2.0 months (fulvestrant); ORR 32% vs 1%

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access